Kadmon Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KDMN research report →
About the company
Kadmon Holdings operates as a biopharmaceutical firm, focusing on the discovery, development, and commercialization of small molecule compounds and biologics, primarily to address inflammatory and fibrotic disorders. Its leading therapeutic asset is KD025, an orally administered selective inhibitor of rho-associated coiled-coil kinase 2 (ROCK2), which is currently undergoing Phase II clinical evaluation for chronic graft-versus-host disease and various fibrotic conditions. Another key oral ROCK inhibitor, KD045, is also in development for fibrotic diseases.
- CEO
- Harlan Waksal
- IPO
- 2016
- Employees
- 127
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $0
- P/E
- -14.39
- P/S
- 0.00
- P/B
- 13.61
- EV/EBITDA
- 0.48
- Div Yield
- 0.00%
- Gross Margin
- 75.86%
- Op Margin
- -1234.09%
- Net Margin
- -1314.10%
- ROE
- -77.31%
- ROIC
- -73.38%
- Revenue
- $8.29M · 62.67%
- Net Income
- $-108,913,000 · -77.48%
- EPS
- $-0.66 · -43.48%
- Op Income
- $-102,281,000
- FCF YoY
- -9.17%
- 52W High
- $9.50
- 52W Low
- $3.45
- 50D MA
- $8.66
- 200D MA
- $5.35
- Beta
- 1.12
- Avg Volume
- 10.03M
Get TickerSpark's AI analysis on KDMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 21 | Waksal Harlan | sell | 177,945 |
| Nov 9, 21 | Waksal Harlan | sell | 655,000 |
| Nov 9, 21 | Waksal Harlan | sell | 982,500 |
| Nov 9, 21 | Waksal Harlan | sell | 2,000,000 |
| Nov 9, 21 | Waksal Harlan | sell | 750 |
| Nov 9, 21 | Waksal Harlan | sell | 1,350,000 |
| Nov 9, 21 | Ryan John L | sell | 100,000 |
| Nov 9, 21 | Ryan John L | sell | 250 |
| Nov 9, 21 | Ryan John L | sell | 150,000 |
| Nov 9, 21 | Ryan John L | sell | 50,000 |
Our KDMN coverage
Recent articles, reports, and earnings notes.
No research on KDMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KDMN report →Similar companies
Peers in the same neighborhood.